Cite
HARVARD Citation
McSheehy, P. et al. (2023). The fibroblast growth factor receptor inhibitor, derazantinib, has strong efficacy in human gastric tumor models and synergizes with paclitaxel in vivo. Anti-cancer drugs. 34 (4), pp. 532-543. [Online].